Redefine X-linked hypophosphatemia (XLH) treatment with a targeted therapy

CRYSVITA® (burosumab-twza) is the only FDA-approved therapy targeting the underlying cause of XLH in adults and children 6 months of age and older.1

CRYSVITA efficacy and safety have been studied in children and adults with XLH.

Discover CRYSVITA’s new Phase 3 data in children and adults.

Redefine X-linked hypophosphatemia (XLH) treatment with a targeted therapy

CRYSVITA® (burosumab-twza) is the only FDA-approved therapy targeting the underlying cause of XLH in adults and children 6 months of age and older.1

CRYSVITA efficacy and safety have been studied in children and adults with XLH.

Discover CRYSVITA’s new Phase 3 data in children and adults.

CRYSVITA® (burosumab-twza) antibody

CRYSVITA® (burosumab-twza) is a breakthrough XLH therapy that targets the underlying cause of the disease

How CRYSVITA may work

Learn about CRYSVITA’s proposed mechanism of action (MOA) on excess fibroblast growth factor 23 (FGF23)

View the Proposed MOA
UltraCare® Patient services provides infromation about how patients and caregivers can access CRYSVITA
UltraCare® Patient services provides infromation about how patients and caregivers can access CRYSVITA

Help your patients gain access to CRYSVITA

UltraCare® Patient Services for CRYSVITA is a program that provides information about how you and your patients can have access to CRYSVITA. Our services are designed to help patients and caregivers understand their insurance coverage and determine their eligibility for financial and patient assistance programs.

Visit UltraCare
Reference
  1. CRYSVITA (burosumab-twza) US Prescribing Information; September 2019.